Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

Media type: E-Article

Title: Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

Contributor: Lleixà, Cinta; Caballero-Ávila, Marta; Pascual-Goñi, Elba; Martín-Aguilar, Lorena; Vidal, Nuria; Tejada, Clara; Valdés-Hevia, Eduardo; Zárate, Elisa; Vesperinas, Ana; Collet, Roger; Franco-Leyva, Teresa; Martínez-Martínez, Laura; Moga, Esther; Cortés-Vicente, Elena; Rojas-García, Ricard; Gómez-Anson, Beatriz; Gil, Anna; González-Mingot, Cristina; Brieva, Luis; Martínez-Yélamos, Sergio; Querol, Luis

Published: Oxford University Press (OUP), 2023

Language: English

DOI: 10.1093/braincomms/fcad109

ISSN: 2632-1297

Keywords: Neurology ; Cellular and Molecular Neuroscience ; Biological Psychiatry ; Psychiatry and Mental health

Origination:

Footnote:

Description: Abstract Multiple sclerosis is a tissue-specific autoimmune disease of the central nervous system in which the antigen(s) remains elusive. Antibodies targeting the flotillin-1/2 complex have been described in 1–2% of the patients in a recent study. Other candidate antigens as anoctamin-2 or neurofascin-155 have been previously described in multiple sclerosis patients, although their clinical relevance remains uncertain. Our study aims to analyse the frequency and clinical relevance of antibodies against neurofascin-155, anoctamin-2 and flotillin-1/2 complex in multiple sclerosis. Serum (n = 252) and CSF (n = 50) samples from 282 multiple sclerosis patients were included in the study. The control group was composed of 260 serum samples (71 healthy donors and 189 with other neuroinflammatory disorders). Anti-flotillin-1/2, anti-anoctamin-2 and anti-neurofascin-155 antibodies were tested by cell-based assays using transfected cells. We identified six multiple sclerosis patients with antibodies against the flotillin-1/2 complex (2.1%) and one multiple sclerosis patient with antibodies against anoctamin-2 (0.35%). All multiple sclerosis patients were negative for anti-neurofascin-155 antibodies. Three of the anti-flotillin-1/2 positive patients showed anti-flotillin-1/2 positivity in other serum samples extracted at different moments of their disease. Immunoglobulin G subclasses of anti-flotillin-1/2 antibodies were predominantly one and three. We confirm that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis.

Access State: Open Access

Search in field:

Recently searched for: